Company Interview / Small-cap, big milestone: Recce secures global patent for anti-infectives

Recce Pharmaceuticals (ASX: RCE) secures an Australian patent for its anti-infective drugs, extending its marketing and manufacturing monopolies to 2037. James Graham highlights the patent's significance in treating bloodstream, diabetic foot ulcer, and viral infections.

With a Phase 2 trial nearly complete, James reports a 100% clinical response rate in treating acute bacterial skin structure infections. The success paves the way for a registration phase three study next year, focusing on diabetic foot ulcers in Indonesia and beyond.

James shares plans for leveraging Indonesian trials' success to secure commercialisation. He mentions $6.8 million R&D rebates from the Australian government, placing the company in a robust position to fund future studies and achieve key clinical milestones.